{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:28:22Z","timestamp":1792736902012,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472979"],"award-info":[{"award-number":["82472979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172775"],"award-info":[{"award-number":["82172775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203159"],"award-info":[{"award-number":["82203159"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.1038\/s41388-026-03681-4","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:13:51Z","timestamp":1771056831000},"page":"856-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1\u207a macrophage-mediated immune evasion in triple-negative breast cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4166-720X","authenticated-orcid":false,"given":"Haizhou","family":"Diao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjie","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-6955","authenticated-orcid":false,"given":"Xinghua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-2484","authenticated-orcid":false,"given":"Xiuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-5368","authenticated-orcid":false,"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9952-9307","authenticated-orcid":false,"given":"Jinguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"3681_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cmet.2024.11.004","volume":"37","author":"F Ligorio","year":"2024","unstructured":"Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F. et al. Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. Cell Metab. 2024;37:330\u2013344.","journal-title":"Cell Metab"},{"key":"3681_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.trecan.2024.02.008","volume":"10","author":"VC Rayson","year":"2024","unstructured":"Rayson VC, Harris MA, Savas P, Hun ML, Virassamy B, Salgado R, et al. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. Trends Cancer. 2024;10:490\u2013506.","journal-title":"Trends Cancer"},{"key":"3681_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.819405","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Pan S, Jian C, Hao L, Dong J, Sun Q, et al. Immunostimulatory properties of chemotherapy in breast cancer: from immunogenic modulation mechanisms to clinical practice. Front Immunol. 2021;12:819405.","journal-title":"Front Immunol"},{"key":"3681_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jare.2023.11.006","volume":"63","author":"J Sun","year":"2024","unstructured":"Sun J, Gui Y, Zhou S, Zheng XL. Unlocking the secrets of aging: Epigenetic reader BRD4 as the target to combatting aging-related diseases. J Adv Res. 2024;63:207\u201318.","journal-title":"J Adv Res"},{"key":"3681_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24137-1","volume":"12","author":"J Dong","year":"2021","unstructured":"Dong J, Li J, Li Y, Ma Z, Yu Y, Wang CY. Transcriptional super enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12:3974.","journal-title":"Nat Commun"},{"key":"3681_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728\u201336.","journal-title":"Mol Cell"},{"key":"3681_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","volume":"78","author":"S Shu","year":"2020","unstructured":"Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovi\u0107 B, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol Cell. 2020;78:1096\u2013113.e8.","journal-title":"Mol Cell"},{"key":"3681_CR8","doi-asserted-by":"publisher","first-page":"e2109133119","DOI":"10.1073\/pnas.2109133119","volume":"119","author":"B Liu","year":"2022","unstructured":"Liu B, Liu X, Han L, Chen X, Wu X, Wu J, et al. BRD4-directed super enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer. Proc Natl Acad Sci USA. 2022;119:e2109133119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3681_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41418-019-0353-2","volume":"27","author":"L Lu","year":"2020","unstructured":"Lu L, Chen Z, Lin X, Tian L, Su Q, An P, et al. Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail. Cell Death Differ. 2020;27:255\u201368.","journal-title":"Cell Death Differ"},{"key":"3681_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s13402-020-00537-1","volume":"43","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xu B, Shi J, Li J, Lu X, Xu L, et al. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol. 2020;43:1049\u201366.","journal-title":"Cell Oncol"},{"key":"3681_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107631","volume":"215","author":"F Spriano","year":"2020","unstructured":"Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacol Ther. 2020;215:107631.","journal-title":"Pharmacol Ther"},{"key":"3681_CR12","doi-asserted-by":"publisher","first-page":"11102","DOI":"10.3390\/ijms222011102","volume":"22","author":"J Sarnik","year":"2021","unstructured":"Sarnik J, Pop\u0142awski T, Tokarz P. BET Proteins as Attractive Targets for Cancer Therapeutics. Int J Mol Sci. 2021;22:11102.","journal-title":"Int J Mol Sci"},{"key":"3681_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X Chu","year":"2024","unstructured":"Chu X, Tian Y, Lv C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol Cancer. 2024;23:150.","journal-title":"Mol Cancer"},{"key":"3681_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bl\u00e9riot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20:983\u201392.","journal-title":"Cell Mol Immunol"},{"key":"3681_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106012","volume":"78","author":"W Jing","year":"2020","unstructured":"Jing W, Guo X, Wang G, Bi Y, Han L, Zhu Q, et al. Breast cancer cells promote CD169(+) macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. Int Immunopharmacol. 2020;78:106012.","journal-title":"Int Immunopharmacol"},{"key":"3681_CR16","doi-asserted-by":"publisher","first-page":"e006808","DOI":"10.1136\/jitc-2023-006808","volume":"11","author":"J Xu","year":"2023","unstructured":"Xu J, Shi Q, Lou J, Wang B, Wang W, Niu J, et al. Chordoma recruits and polarizes tumor-associated macrophages by secreting CCL5 to promote malignant progression. J Immunother Cancer. 2023;11:e006808.","journal-title":"J Immunother Cancer"},{"key":"3681_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2170-4","volume":"10","author":"J Mu","year":"2019","unstructured":"Mu J, Sun P, Ma Z, Sun P. BRD4 promotes tumor progression and NF-\u03baB\/CCL2-dependent tumor-associated macrophage recruitment in GIST. Cell Death Dis. 2019;10:935.","journal-title":"Cell Death Dis"},{"key":"3681_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s43018-021-00258-w","volume":"2","author":"M Tu","year":"2021","unstructured":"Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Li X, et al. TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer. 2021;2:1185\u2013203.","journal-title":"Nat Cancer"},{"key":"3681_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fimmu.2020.00089","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Fu Y, Yang B, Guo E, Wu Y, Huang J, et al. BRD4 Inhibition by AZD5153 promotes antitumor immunity via depolarizing M2 macrophages. Front Immunol. 2020;11:89.","journal-title":"Front Immunol"},{"key":"3681_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102620","volume":"9","author":"Y Yin","year":"2022","unstructured":"Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, et al. Colorectal cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages. Adv Sci. 2022;9:2102620.","journal-title":"Adv Sci."},{"key":"3681_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41392-024-02042-5","volume":"9","author":"X Jiang","year":"2024","unstructured":"Jiang X, Wang J, Lin L, Du L, Ding Y, Zheng F, et al. Macrophages promote pre-metastatic niche formation of breast cancer through aryl hydrocarbon receptor activity. Signal Transduct Target Ther. 2024;9:352.","journal-title":"Signal Transduct Target Ther"},{"key":"3681_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101377","volume":"5","author":"J Sprooten","year":"2024","unstructured":"Sprooten J, Vanmeerbeek I, Datsi A, Govaerts J, Naulaerts S, Laureano RS, et al. Lymph node and tumor-associated PD-L1(+) macrophages antagonize dendritic cell vaccines by suppressing CD8(+) T cells. Cell Rep Med. 2024;5:101377.","journal-title":"Cell Rep Med"},{"key":"3681_CR23","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41590-024-01985-9","volume":"25","author":"D Raychaudhuri","year":"2024","unstructured":"Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, et al. Histone lactylation drives CD8(+) T-cells metabolism and function. Nat Immunol. 2024;25:2140\u201351.","journal-title":"Nat Immunol"},{"key":"3681_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01841-8","volume":"22","author":"SW Yue","year":"2023","unstructured":"Yue SW, Liu HL, Su HF, Luo C, Liang HF, Zhang BX, et al. m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism. Mol Cancer. 2023;22:137.","journal-title":"Mol Cancer"},{"key":"3681_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8:210.","journal-title":"Signal Transduct Target Ther"},{"key":"3681_CR26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53:1334\u201347.","journal-title":"Nat Genet"},{"key":"3681_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53695-0","volume":"9","author":"BM Boac","year":"2019","unstructured":"Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, et al. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep. 2019;9:17496.","journal-title":"Sci Rep"},{"key":"3681_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/0008-5472.CAN-12-2633","volume":"73","author":"V Maire","year":"2013","unstructured":"Maire V, N\u00e9mati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2013;73:813\u201323.","journal-title":"Cancer Res"},{"key":"3681_CR29","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gy\u0151rffy","year":"2021","unstructured":"Gy\u0151rffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139.","journal-title":"Comput Struct Biotechnol J"},{"key":"3681_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"3681_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1919082","volume":"2019","author":"D Lu","year":"2019","unstructured":"Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, et al. Beyond T Cells: Understanding the Role of PD-1\/PD-L1 in Tumor-Associated Macrophages. J Immunol Res. 2019;2019:1919082.","journal-title":"J Immunol Res"},{"key":"3681_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.142","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Wright JH, Smythe KS, Fiorenza S, Shaw AN, Gauthier J, et al. PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T-cells immunotherapy efficacy. Hemasphere. 2024;8:e142.","journal-title":"Hemasphere"},{"key":"3681_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/cgt.2016.19","volume":"23","author":"M Thorn","year":"2016","unstructured":"Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, et al. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther. 2016;23:188\u201398.","journal-title":"Cancer Gene Ther"},{"key":"3681_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41388-018-0449-z","volume":"38","author":"P Guha","year":"2019","unstructured":"Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, et al. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene. 2019;38:533\u201348.","journal-title":"Oncogene"},{"key":"3681_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108354","volume":"243","author":"J Guo","year":"2023","unstructured":"Guo J, Zheng Q, Peng Y. BET proteins: Biological functions and therapeutic interventions. Pharmacol Ther. 2023;243:108354.","journal-title":"Pharmacol Ther"},{"key":"3681_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03185-6","volume":"21","author":"F Zhang","year":"2024","unstructured":"Zhang F, Zhou J, Lu P, Zhang X, Yang L, Wu J, et al. Lactylation of histone by BRD4 regulates astrocyte polarization after experimental subarachnoid hemorrhage. J Neuroinflammation. 2024;21:186.","journal-title":"J Neuroinflammation"},{"key":"3681_CR37","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","volume":"81","author":"SJ Hogg","year":"2021","unstructured":"Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, et al. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition. Mol Cell. 2021;81:2183\u2013200.e13.","journal-title":"Mol Cell"},{"key":"3681_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.495","volume":"5","author":"M Gu","year":"2024","unstructured":"Gu M, Ren B, Fang Y, Ren J, Liu X, Wang X, et al. Epigenetic regulation in cancer. MedComm (2020). 2024;5:e495.","journal-title":"MedComm (2020)"},{"key":"3681_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1450325","volume":"14","author":"M Jemal","year":"2024","unstructured":"Jemal M, Getinet M, Amare GA, Tegegne BA, Baylie T, Mengistu EF, et al. Nonmetabolic enzyme function of pyruvate kinase M2 in breast cancer. Front Oncol. 2024;14:1450325.","journal-title":"Front Oncol"},{"key":"3681_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189089","volume":"1879","author":"S Upadhyay","year":"2024","unstructured":"Upadhyay S, Khan S, Hassan MI. Exploring the diverse role of pyruvate kinase M2 in cancer: Navigating beyond glycolysis and the Warburg effect. Biochim Biophys Acta Rev Cancer. 2024;1879:189089.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3681_CR41","first-page":"1021","volume":"21","author":"G Jiang","year":"2020","unstructured":"Jiang G, Deng W, Liu Y, Wang C. General mechanism of JQ1 in inhibiting various types of cancer. Mol Med Rep. 2020;21:1021\u201334.","journal-title":"Mol Med Rep"},{"key":"3681_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2174\/0113894501269090231012090351","volume":"24","author":"M Zhang","year":"2023","unstructured":"Zhang M, Li Y, Zhang Z, Zhang X, Wang W, Song X, et al. BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review. Curr Drug Targets. 2023;24:1079\u201392.","journal-title":"Curr Drug Targets"},{"key":"3681_CR43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904\u201317.","journal-title":"Cell"},{"key":"3681_CR44","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/leu.2017.10","volume":"31","author":"S Peirs","year":"2017","unstructured":"Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017;31:2037\u201347.","journal-title":"Leukemia"},{"key":"3681_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02258-1","volume":"24","author":"M Wan","year":"2025","unstructured":"Wan M, Pan S, Shan B, Diao H, Jin H, Wang Z, et al. Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment. Molecular Cancer. 2025;24:61.","journal-title":"Molecular Cancer"},{"key":"3681_CR46","doi-asserted-by":"publisher","first-page":"15163","DOI":"10.3390\/ijms232315163","volume":"23","author":"JX Zhou","year":"2022","unstructured":"Zhou JX, Agborbesong E, Li LX, Li X. Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. Int J Mol Sci. 2022;23:15163.","journal-title":"Int J Mol Sci"},{"key":"3681_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15290-0","volume":"11","author":"M Yin","year":"2020","unstructured":"Yin M, Guo Y, Hu R, Cai WL, Li Y, Pei S, et al. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020;11:1833.","journal-title":"Nat Commun"},{"key":"3681_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112034","volume":"392","author":"X Jing","year":"2020","unstructured":"Jing X, Shao S, Zhang Y, Luo A, Zhao L, Zhang L, et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp Cell Res. 2020;392:112034.","journal-title":"Exp Cell Res"},{"key":"3681_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11060-024-04889-8","volume":"171","author":"Y Liu","year":"2024","unstructured":"Liu Y, Cai L, Wang H, Yao L, Wu Y, Zhang K. et al. BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression. J Neuroonco. 2024;171:669\u2013679.","journal-title":"J Neuroonco"},{"key":"3681_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.718","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, et al. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin Transl Med. 2022;12:e718.","journal-title":"Clin Transl Med"},{"key":"3681_CR51","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","volume":"6","author":"GP Hartley","year":"2018","unstructured":"Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018;6:1260\u201373.","journal-title":"Cancer Immunol Res"},{"key":"3681_CR52","doi-asserted-by":"publisher","first-page":"13062","DOI":"10.3390\/ijms241713062","volume":"24","author":"S Kim","year":"2023","unstructured":"Kim S, Jeon SH, Han MG, Kang MH, Kim IA. BRD4 inhibition enhances the antitumor effects of radiation therapy in a murine breast cancer model. Int J Mol Sci. 2023;24:13062.","journal-title":"Int J Mol Sci"},{"key":"3681_CR53","doi-asserted-by":"publisher","first-page":"e003793","DOI":"10.1136\/jitc-2021-003793","volume":"10","author":"D Sheng","year":"2022","unstructured":"Sheng D, Ma W, Zhang R, Zhou L, Deng Q, Tu J, et al. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization. J Immunother Cancer. 2022;10:e003793.","journal-title":"J Immunother Cancer"},{"key":"3681_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1158859","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li F, Hua M, Liang M, Song C. Role of GM-CSF in lung balance and disease. Front Immunol. 2023;14:1158859.","journal-title":"Front Immunol"},{"key":"3681_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1074-7613(01)00218-7","volume":"15","author":"Y Shibata","year":"2001","unstructured":"Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15:557\u201367.","journal-title":"Immunity"},{"key":"3681_CR56","first-page":"129","volume":"20","author":"JL Owen","year":"2007","unstructured":"Owen JL, Torroella-Kouri M, Handel-Fernandez ME, Iragavarapu-Charyulu V. GM-CSF upregulates the expression of CCL2 by T lymphocytes in mammary tumor-bearing mice. Int J Mol Med. 2007;20:129\u201336.","journal-title":"Int J Mol Med"},{"key":"3681_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni T, Mavrianou N, Gavalas NG, Tzannis K, Arapinis C, Liontos M, et al. JQ1 inhibits tumor growth in combination with cisplatin and suppresses JAK\/STAT signaling pathway in ovarian cancer. Eur J Cancer. 2020;126:125\u201335.","journal-title":"Eur J Cancer"},{"key":"3681_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01374-y","volume":"20","author":"QX Rong","year":"2021","unstructured":"Rong QX, Wang F, Guo ZX, Hu Y, An SN, Luo M, et al. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer\/T-cell lymphoma. Mol Cancer. 2021;20:80.","journal-title":"Mol Cancer"},{"key":"3681_CR59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","volume":"394","author":"AS Leal","year":"2017","unstructured":"Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett. 2017;394:76\u201387.","journal-title":"Cancer Lett"},{"key":"3681_CR60","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12:4935\u201348.","journal-title":"Theranostics"},{"key":"3681_CR61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575\u201380.","journal-title":"Nature"},{"key":"3681_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jare.2024.11.010","volume":"75","author":"XT Hu","year":"2024","unstructured":"Hu XT, Wu XF, Xu JY, Xu X. Lactate-mediated lactylation in human health and diseases: progress and remaining challenges. J Adv Res. 2024;75:229\u2013248.","journal-title":"J Adv Res"},{"key":"3681_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2421496121","volume":"121","author":"G Zhai","year":"2024","unstructured":"Zhai G, Niu Z, Jiang Z, Zhao F, Wang S, Chen C, et al. DPF2 reads histone lactylation to drive transcription and tumorigenesis. Proceedings of the National Academy of Sciences. 2024;121:e2421496121.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"3681_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02008-9","volume":"23","author":"F Li","year":"2024","unstructured":"Li F, Si W, Xia L, Yin D, Wei T, Tao M, et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer. 2024;23:90.","journal-title":"Mol Cancer"},{"key":"3681_CR65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tig.2021.09.009","volume":"38","author":"X Dai","year":"2022","unstructured":"Dai X, Lv X, Thompson EW, Ostrikov KK. Histone lactylation: epigenetic mark of glycolytic switch. Trends Genet. 2022;38:124\u20137.","journal-title":"Trends Genet"},{"key":"3681_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2018.08.014","volume":"104","author":"P Fan","year":"2018","unstructured":"Fan P, Wang B, Meng Z, Zhao J, Jin X. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma. Int J Biochem Cell Biol. 2018;104:1\u20138.","journal-title":"Int J Biochem Cell Biol"},{"key":"3681_CR67","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021;124:1478\u201390.","journal-title":"Br J Cancer"},{"key":"3681_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106833","volume":"140","author":"A Wahi","year":"2023","unstructured":"Wahi A, Manchanda N, Jain P, Jadhav HR. Targeting the epigenetic reader \u201cBET\u201d as a therapeutic strategy for cancer. Bioorg Chem. 2023;140:106833.","journal-title":"Bioorg Chem"},{"key":"3681_CR69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/jir.2014.0149","volume":"35","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res. 2015;35:585\u201399.","journal-title":"J Interferon Cytokine Res"},{"key":"3681_CR70","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI28828","volume":"116","author":"G Gallina","year":"2006","unstructured":"Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116:2777\u201390.","journal-title":"J Clin Invest"},{"key":"3681_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.706186","volume":"12","author":"HM Lazarus","year":"2021","unstructured":"Lazarus HM, Ragsdale CE, Gale RP, Lyman GH. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Front Immunol. 2021;12:706186.","journal-title":"Front Immunol"},{"key":"3681_CR72","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/gutjnl-2021-324109","volume":"71","author":"LI Ruffolo","year":"2022","unstructured":"Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, et al. GM-CSF drives myelopoiesis, recruitment and polarization of tumor-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022;71:1386\u201398.","journal-title":"Gut"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03681-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:02:59Z","timestamp":1771887779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,3,17]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03681-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}